about
STAT1 activation regulates proliferation and differentiation of renal progenitorsThe consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domainTargeting SH2 domains in breast cancerNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewChemical probes that competitively and selectively inhibit Stat3 activationGaliellalactone inhibits stem cell-like ALDH-positive prostate cancer cellsAngiotensin II Type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNFα production.Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo.A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesisInhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burdenA phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.Novel method of monitoring trace cytokines and activated STAT molecules in the paws of arthritic mice using multiplex bead technology.Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model.Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathwayγ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent.Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity.Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer.A membrane penetrating peptide aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells.Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence.The frail renin-angiotensin system.Overexpression of gelsolin reduces the proliferation and invasion of colon carcinoma cells.Transkingdom RNA interference (tkRNAi) as a new delivery tool for therapeutic RNA.Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.Potential for statins in the chemoprevention and management of hepatocellular carcinoma.Hydrophobic and electrostatic interactions between cell penetrating peptides and plasmid DNA are important for stable non-covalent complexation and intracellular delivery.Crispene E, a cis-clerodane diterpene inhibits STAT3 dimerization in breast cancer cells.A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion.Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.The influence of the substitution pattern on the molecular conformation of ureido-1,2,5-oxadiazoles, related to STAT3 inhibitors: chemical behavior and structural investigation.Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3).Akt signaling pathway: a target for radiosensitizing human malignant glioma.Normal breast tissue DNA methylation differences at regulatory elements are associated with the cancer risk factor age.Angiotensin Receptor Blockade Modulates NFκB and STAT3 Signaling and Inhibits Glial Activation and Neuroinflammation Better than Angiotensin-Converting Enzyme Inhibition.Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor.Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer.
P2860
Q24338667-E92F8338-0D0B-4A22-B54C-41A49CA65E57Q26861758-5EAC1CF9-7CFD-48BA-B2B8-A946D103DF80Q27014674-6310210D-48B7-4B82-9892-CFB3D9634ECFQ27304386-3A28FE32-9F53-4CE5-B9CD-B378493F0EB3Q28475010-B6E699CA-60C1-4E6E-8E3B-31BB7E07B8A5Q28478976-E6CEC846-3F7A-4261-855F-E16347790A65Q30426697-0EF04C4A-4F42-41B7-8516-C6AF0BECE116Q30576918-4BE35E97-3DBA-4790-AD9A-B11104D9C81FQ33597235-92A34627-306B-4719-A9CD-774F310750FEQ33628532-02B58A89-B915-4CA1-BFF7-99D42316A7DCQ33661939-C553EC27-3388-49DA-9968-804CF4415838Q33745759-96454525-3887-40B4-A50E-411F0CF59787Q34177244-D25DCAFC-2BE1-4462-A0DC-8405F7E4475BQ34342251-7E5E385A-4B0B-4754-A8DC-B3EF5A96D5B5Q34919598-CCC0BF37-5FEB-4935-A654-D20B9AC8ABE4Q35538455-A922F7E0-185D-4AAF-AC61-97346D4AF338Q35869426-00E5262C-D0CB-4211-896B-43BD8F2D8224Q36245502-62CC5682-9432-4192-B964-0A8CCA73CD09Q36894985-AB59AAD4-1F4D-4124-9605-0110F4763A9AQ37113973-C06350B2-4107-40A2-AFC0-02665AF2EFD8Q37122224-FCB220D9-5F7C-488C-B5C0-02EAE0F93467Q37150747-9EC7882D-9509-4F09-9781-3DD5D9676535Q37297568-AA1BE19A-5946-4D34-8E30-718D382A5364Q37600906-B9F54E5D-AA06-4FAC-8B3B-080D67CE2BD1Q37694029-A30B0018-EA06-401C-873E-1F491FFD727CQ37705457-F766E8D4-D3C8-4E9A-8CFD-F42CB0D67426Q37830361-06A7AB67-1F8D-4D9D-A9B0-08FD0D17C6A3Q37869903-B28D4DAA-9431-4940-926A-21FEB53137DCQ38030991-A0F23753-22BD-4664-B2BE-B0AAFE07E56EQ38741797-7A254E23-17E0-4718-B220-6B7E658585A1Q38905585-38CDEB3F-DD31-4C0D-B248-415F81DFB491Q39012525-8A280244-F889-4BC7-AC79-94EAFE7DA544Q39159381-B86687E8-FE1E-4159-8AC4-B3BC917FA717Q39316723-F20FD0D3-D555-4E61-9880-CF972BE3C41FQ39523484-309CEBB3-9006-4AF4-A846-65165D8C71BCQ39712690-E88F67F9-41E5-4239-9845-C2DA526DAD78Q40128723-4AE678CA-3E75-478A-8908-771DD4B0071CQ40212788-59F9E3BB-188F-47F9-B2E2-28FD0ECC57DBQ42385863-4E7965D9-545C-4333-8C19-0675B94AE5DCQ43494045-6F8BB9B8-81CC-4486-AD69-A6FF2459E930
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
STAT 3 as a target for cancer drug discovery.
@ast
STAT 3 as a target for cancer drug discovery.
@en
STAT 3 as a target for cancer drug discovery.
@nl
type
label
STAT 3 as a target for cancer drug discovery.
@ast
STAT 3 as a target for cancer drug discovery.
@en
STAT 3 as a target for cancer drug discovery.
@nl
prefLabel
STAT 3 as a target for cancer drug discovery.
@ast
STAT 3 as a target for cancer drug discovery.
@en
STAT 3 as a target for cancer drug discovery.
@nl
P1476
STAT 3 as a target for cancer drug discovery.
@en
P2093
Daniela Barlocco
P304
P356
10.2174/092986708783955464
P577
2008-01-01T00:00:00Z